摘要
放疗是治疗肝细胞癌患者的重要策略之一。发展新的放疗敏化剂是一个关键问题,因为肝细胞癌的固有放射敏感性低。野生型NBS1抑制肽(wtNIP)可以通过取消ATM-NBS1相互作用并阻止DNA损伤应答来提高一些癌细胞系的放射敏感性。在此我们通过把CNGRC血管生成血管引导肽NGR和wtNIP肽相结合开发了一个新NGR接合肽(NGR-sR9-wtNIP)。我们测试了融合肽的内化,Hep3B细胞毒性,肿瘤定位和移植人肝细胞癌的裸鼠的毒性。我们也研究了NGR-sR9-wtNIP的放射增敏活性。我们发现NGR-sR9-wtNIP可以抑制放射诱导的NBS1磷酸化并诱导Hep3B细胞的放射敏化。与IR相结合,NGR-sR9-wtNIP明显抑制了移植小鼠的肿瘤生长。此外,我们的数据有力地证明了NGR-sR9-wtNIP具有用于肝细胞癌放疗的放射增敏潜力。
关键词: DNA损伤应答,NGR,放射,NIP(NBS1抑制肽),放射敏化
Current Cancer Drug Targets
Title:A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Volume: 15 Issue: 6
Author(s): Jinlu Ma, Dan Zhang, Xia Ying, Ying Zhao, Chenchen He, Qing Zhu and Suxia Han
Affiliation:
关键词: DNA损伤应答,NGR,放射,NIP(NBS1抑制肽),放射敏化
摘要: Radiotherapy is one of the important treatment strategies for patients with advanced hepatocellular carcinomas. Developing novel sensitizers for radiotherapy is a key issue due to the low intrinsic radiosensitivity of hepatocellular carcinomas. It was reported the wild-type NBS1 inhibitory peptide (wtNIP) can increase radiosensitivity in several cancer cell lines by abrogating ATM-NBS1 interaction and interrupting cellular DNA damage response. Here, we developed a novel NGRconjugated peptide (NGR-sR9-wtNIP) through coupling the CNGRC angiogenic vessel-homing peptide NGR with the wtNIP peptide. Fusion peptide was tested for internalization, cytotoxicity in Hep3B cells and for tumor localization, and for toxicity in nude mice bearing human hepatocellular carcinomas xenografts. The radiosensitizing activity of NGR-sR9-wtNIP was investigated as well. We found that NGR-sR9-wtNIP can inhibit irradiation induced NBS1 phosphorylation and induce radiosensitization in Hep3B cells. When combined with IR, NGR-sR9-wtNIP suppressed tumor growth obviously in xenograft mice. In addition, the fusion peptide localized in tumor tissue specifically and barely led to any side effects on mice. Taken together, our data strongly suggest that NGRsR9- wtNIP has radiosensitizing potential for radiotherapy of hepatocellular carcinomas.
Export Options
About this article
Cite this article as:
Jinlu Ma, Dan Zhang, Xia Ying, Ying Zhao, Chenchen He, Qing Zhu and Suxia Han , A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization, Current Cancer Drug Targets 2015; 15 (6) . https://dx.doi.org/10.2174/1568009615666150408114817
DOI https://dx.doi.org/10.2174/1568009615666150408114817 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Nanotheranostics in Evidence Based Personalized Medicine
Current Drug Targets MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA Synthesis and Evaluation of Heterocycles Based Chalcone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Regulation of Apoptosis and Cell Survival by Resveratrol
Mini-Reviews in Organic Chemistry Recent Advances in Mesoporous Silica and Gold Based Nanovectors in Anticancer Drug Delivery System
Current Organic Chemistry The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer
Combinatorial Chemistry & High Throughput Screening Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology Histone Variants and Composition in the Developing Brain: Should MeCP2 Care?
Current Topics in Medicinal Chemistry MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design Interrelation of Major Depression and Antidepressant Transcriptomics
Current Psychopharmacology CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis
Current Pharmaceutical Design Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Concentration-Dependent Bimodal Effect of Specific 18 kDa Translocator Protein (TSPO) Ligands on Cell Death Processes Induced by Ammonium Chloride: Potential Implications for Neuropathological Effects Due to Hyperammonemia
CNS & Neurological Disorders - Drug Targets Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria
Current Clinical Pharmacology